[Antibody-drug conjugates: design and clinical progress]

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antibody-drug conjugates (ADCs) represent a significant advancement in cancer therapy.
• ADCs combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs.

Purpose of the Study:

• To review the development strategies and progress of ADCs over the past decade.
• To introduce and characterize representative ADCs currently in development pipelines.
• To propose future research directions for ADCs.

Main Methods:

• Literature review of antibody-drug conjugate development.
• Analysis of recent advancements and clinical progress in ADC therapy.
• Characterization of novel ADCs and their unique features.

Main Results:

• ADCs demonstrate distinct advantages over conventional chemotherapy and antibody therapies.
• Significant progress has been made in ADC development over the last ten years.
• Emerging ADCs exhibit novel features and therapeutic potential.

Conclusions:

• ADCs are a powerful therapeutic modality in oncology.
• Continued innovation in ADC design and application is expected.
• Future research should focus on optimizing ADC efficacy and overcoming resistance mechanisms.